DRUG TRANSPORT IN THE LIVER - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 397

115. Zegers MM, Hoekstra D. 1998. Mechanisms and functional features of polarized
membrane traffic in epithelial and hepatic cells. Biochem J 336(Pt 2):257-269.
116. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O. 2006.
Functional expression of sinusoidal and canalicular hepatic drug transporters in the
differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28(1-2):109-117.
117. Boyer JL. 1997. Isolated hepatocyte couplets and bile duct units: novel preparations for
the in vitro study of bile secretory function. Cell Biol Toxicol 13(4-5):289-300.
118. Coleman R, Wilton JC, Stone V, Chipman JK. 1995. Hepatobiliary function and toxicity
in vitro using isolated hepatocyte couplets. Gen Pharmacol 26(7):1445-1453.
119. Patel NJ, Zamek-Gliszczynski MJ, Zhang P, Han YH, Jansen PL, Meier PJ, Stieger B,
Brouwer KLR. 2003. Phenobarbital alters hepatic Mrp2 function by direct and indirect
interactions. Mol Pharmacol 64(1):154-159.
120. Nezasa K, Tian X, Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, Brouwer KLR. 2006.
Altered hepatobiliary disposition of 5 (and 6)-carboxy-2 ,7 -dichlorofluorescein in
Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. Drug Metab Dispos 34(4):718-
723.
121. Moffit JS, Aleksunes LM, Maher JM, Scheffer GL, Klaassen CD, Manautou JE. 2006.
Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3
and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha. J
Pharmacol Exp Ther 317(2):537-545.
122. Guo GL, Choudhuri S, Klaassen CD. 2002. Induction profile of rat organic anion
transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers
that activate gene expression through ligand-activated transcription factor pathways. J
Pharmacol Exp Ther 300(1):206-212.
123. Lee J, Azzaroli F, Wang L, Soroka CJ, Gigliozzi A, Setchell KD, Kramer W, Boyer
JL. 2001. Adaptive regulation of bile salt transporters in kidney and liver in obstructive
cholestasis in the rat. Gastroenterology 121(6):1473-1484.
124. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. 2001. Transport of methotrexate
(MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of poly-
glutamylation on MTX transport. Cancer Res 61(19):7225-7232.
125. Aoki Y, Cioca DP, Oidaira H, Kamiya J, Kiyosawa K. 2003. RNA interference may be
more potent than antisense RNA in human cancer cell lines. Clin Exp Pharmacol Physiol
30(1-2):96-102.
126. Summerton J, Weller D. 1997. Morpholino antisense oligomers: design, preparation,
and properties. Antisense Nucleic Acid Drug Dev 7(3):187-195.
127. Summerton J. 1999. Morpholino antisense oligomers: the case for an RNase H-
independent structural type. Biochim Biophys Acta 1489(1):141-158.
128. Ghibellini G, Johnson BM, Kowalsky RJ, Heizer WD, Brouwer KLR. 2004. A novel
method for the determination of biliary clearance in humans. AAPS J 6(4):e33.
129. Hendrikse NH, Kuipers F, Meijer C, Havinga R, Bijleveld CM, van der Graaf WT,
Vaalburg W, de Vries EG. 2004. In vivo imaging of hepatobiliary transport function
mediated

by multidrug resistance associated protein and P-glycoprotein. Cancer

Chemother Pharmacol 54(2):131-138.
130. Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, Obayashi S, Nakao R,
Suzuki K, Sugiyama Y, Suhara T. 2006. In vivo evaluation of P-glycoprotein function at
the blood-brain barrier in nonhuman primates using [ 11 C]verapamil. J Pharmacol Exp
Ther 316(2):647-653.